Form 4: Director Stock Option and RSU Grant at Tarsus Pharmaceuticals

Katherine Goodrich, a Director at Tarsus Pharmaceuticals, Inc., received a stock option grant and Restricted Stock Units (RSUs) on June 25, 2026.

Summary

• Katherine Goodrich, a Director at Tarsus Pharmaceuticals, Inc. (TARS), was granted a stock option and Restricted Stock Units (RSUs) on June 25, 2026.
• The stock option has an exercise price of $64.34 and is for 3,837 shares, with an expiration date of June 24, 2036.
• The RSUs granted are for 2,417 shares.
• Both the stock option and RSUs are subject to vesting in full on the one-year anniversary of the grant date, contingent upon continuous service as a non-employee director.
• These grants were made in connection with the company's 2026 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine equity grants to a director rather than significant financial performance or strategic shifts.

Positives

• Director Katherine Goodrich received equity awards, indicating continued commitment and alignment with the company's performance.
• The stock option grant at a price of $64.34 suggests a belief in future stock appreciation from the current trading price.
• The grant of RSUs further incentivizes long-term performance and shareholder value.

Risks

• Vesting of the stock option and RSUs is contingent upon continuous service, meaning any departure before the vesting date would result in forfeiture.
• The exercise price of the stock option ($64.34) implies that the stock price needs to increase significantly to be profitable for the option holder.

Future Outlook

The future outlook for the stock option and RSUs is tied to the company's performance and stock price appreciation, as they are subject to vesting and have a future expiration date.

Industry Context

StockSavvy.ai notes that grants of stock options and RSUs to directors are standard practice in the pharmaceutical industry to align executive and director interests with those of shareholders and to attract and retain talent.

Stakeholder Impact

• Shareholders: The grants align director incentives with shareholder interests, potentially leading to decisions that enhance shareholder value. However, dilution from future exercise of options could be a minor concern if not managed.
• Employees: Standard practice that does not directly impact employees unless they are also recipients of similar grants.
• Management: Reinforces the alignment of board members with company performance goals.

Next Steps

• Continuous service by Katherine Goodrich as a non-employee director for one year from the grant date to satisfy vesting conditions for the stock option and RSUs.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Katherine Goodrich, Director, Stock Option, Restricted Stock Units, RSU, Equity Grant, Beneficial Ownership, SEC Filing